Fiche centre
K2 Medical Research, LLC
Maitland — United States
Essais liés7clinical trials
VilleMaitlandlocalisation
PaysUnited Stateslocalisation
SourcelocaleCSV/MySQL
Informations
centreSynchronisé depuis ClinicalTrials.gov — NCT04770220
Essais cliniques associés
7| Molécule | Indication / population | Phase | NCT | Titre | Statut |
|---|---|---|---|---|---|
| LY3954068 | Alzheimer | Phase 1 | NCT06297590 | A First-In-Human Study of LY3954068 in Participants With Early Symptomatic Alzheimer's Disease | RECRUITING |
| Experimental: ALZ-801 | Alzheimer | Phase 3 | NCT04770220 | APOLLOE4 — An Efficacy and Safety Study of ALZ-801 in APOE4/4 Early AD Subjects | COMPLETED |
| RO7126209 | Alzheimer | Phase 1/2 | NCT04639050 | Brainshuttle AD: A Multiple Ascending Dose Study to Investigate the Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of RO7126209 Following Intravenous Infusion in Participants With Prodromal or Mild to Moderate Alzheimer's Disease | ACTIVE_NOT_RECRUITING |
| Trontinemab | Alzheimer | Phase 3 | NCT07717411 | PrevenTRON — A Study of Trontinemab in Cognitively Unimpaired Individuals at Risk for Progression to Symptomatic Alzheimer's Disease | RECRUITING |
| Trontinemab | Alzheimer | Phase 3 | NCT07169578 | TRONTIER 1 — A Study of Trontinemab in Participants With Early Symptomatic Alzheimer's Disease | ACTIVE_NOT_RECRUITING |
| CT1812 | Alzheimer | Phase 2 | NCT05531656 | A Study to Evaluate the Safety and Efficacy of CT1812 in Early Alzheimer's Disease | ACTIVE_NOT_RECRUITING |
| VY1706 Low dose | Alzheimer | Phase 1 | NCT07764146 | An Open Label Dose Escalation Study of VY1706 in Participants With Early Alzheimer's Disease | RECRUITING |